UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply

Alimentary pharmacology & therapeutics, 2024-04, Vol.59 (8), p.1011-1011

2024

Volltextzugriff (PDF)

Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?

World journal of gastroenterology : WJG, 2017-09, Vol.23 (35), p.6385-6402

2017

Volltextzugriff (PDF)

Editorial: delving into the natural history of Crohn’s disease and the impact of medical therapy

Alimentary pharmacology & therapeutics, 2022-01, Vol.55 (1), p.108-109

2022

Volltextzugriff (PDF)

Editorial: does anti‐TNF “treatment persistence” always equate to “effective treatment”? Only objective disease assessments can answer the question

Alimentary pharmacology & therapeutics, 2021-09, Vol.54 (5), p.718-719

2021

Volltextzugriff (PDF)

Dose intensification strategy influences infliximab pharmacokinetics but not clinical response after the same number of doses

Journal of gastroenterology and hepatology, 2023-05, Vol.38 (5), p.724-732

2023

Volltextzugriff (PDF)

Letter: choosing between ustekinumab and vedolizumab in anti‐TNF refractory Crohn’s disease—the devil is in the detail

Alimentary pharmacology & therapeutics, 2020-08, Vol.52 (3), p.561-562

2020

Volltextzugriff (PDF)

Editorial: direct costs are only the tip of the iceberg in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2020-09, Vol.52 (5), p.879-880

2020

Volltextzugriff (PDF)

Dietary sorbitol and mannitol: food content and distinct absorption patterns between healthy individuals and patients with irritable bowel syndrome

Journal of human nutrition and dietetics, 2014-04, Vol.27 (s2), p.263-275

2014

Volltextzugriff (PDF)

Systematic review: fatigue in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2010-07, Vol.32 (2), p.131-143

2010

Volltextzugriff (PDF)

Sleep and physical activity measured by accelerometry in Crohn's disease

Alimentary pharmacology & therapeutics, 2015-05, Vol.41 (10), p.991-1004

2015

Volltextzugriff (PDF)

Clinical trial: Combination allopurinol‐thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study)

Alimentary pharmacology & therapeutics, 2024-02, Vol.59 (4), p.504-514

2024

Volltextzugriff (PDF)

Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease

Inflammatory bowel diseases, 2019-09, Vol.25 (9), p.1462-1473

2019

Volltextzugriff (PDF)

Editorial: methotrexate vs azathioprine—do differential rates of discontinuation settle the debate? Authors’ reply

Alimentary pharmacology & therapeutics, 2020-11, Vol.52 (9), p.1529-1530

2020

Volltextzugriff (PDF)

Letter: overcoming secondary loss of response to infliximab—it is not the drug, it is how you use it

Alimentary pharmacology & therapeutics, 2018-11, Vol.48 (9), p.1028-1029

2018

Volltextzugriff (PDF)

Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2020-10, Vol.52 (7), p.1174-1184

2020

Volltextzugriff (PDF)

Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability

World journal of gastroenterology : WJG, 2020-09, Vol.26 (36), p.5437-5449

2020

Volltextzugriff (PDF)

Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy

Intestinal research, 2022, 20(1), , pp.101-113

2022

Volltextzugriff (PDF)

Predicting response after infliximab salvage in acute severe ulcerative colitis

Journal of gastroenterology and hepatology, 2018-07, Vol.33 (7), p.1347-1352

2018

Volltextzugriff (PDF)

The Utility of Faecal Calprotectin, Lactoferrin and Other Faecal Biomarkers in Discriminating Endoscopic Activity in Crohn's Disease: A Systematic Review and Meta-Analysis

Biomedicines, 2023-05, Vol.11 (5), p.1408

2023

Volltextzugriff (PDF)

The synergy of dual faecal immunochemical and faecal calprotectin testing for accurate assessment of endoscopic and histological activity in inflammatory bowel disease

Therapeutic advances in gastroenterology, 2024-01, Vol.17, p.17562848241237895-17562848241237895

2024

Volltextzugriff (PDF)

Authors’ Response to Letter to Editor: “Evaluating Serum Free Thiols in Inflammatory Bowel Disease: Contribution of Albumin to Extracellular Free Thiol Status”

Inflammatory bowel diseases, 2024-08, Vol.30 (8), p.1441-1441

2024

Volltextzugriff (PDF)

Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study

Journal of Crohn's and colitis, 2018-02, Vol.12 (3), p.289-297

2018

Volltextzugriff (PDF)

Intestinal Ultrasound in the Assessment of Luminal Crohn’s Disease

Gastrointestinal disorders (Basel, Switzerland), 2022-09, Vol.4 (4), p.249-262

2022

Volltextzugriff (PDF)

New choices, new challenges: Anti-TNF versus anti-integrin molecule therapy in IBD

Journal of gastroenterology and hepatology, 2016-06, Vol.31 (S1), p.10-11

van Langenberg, Daniel R

2016

Volltextzugriff (PDF)

Challenges and Strategies to Optimising the Quality of Small Bowel Magnetic Resonance Imaging in Crohn’s Disease

Diagnostics (Basel), 2022-10, Vol.12 (10), p.2533

2022

Volltextzugriff (PDF)

1 – 25 von 912

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(812)
Mit Volltextzugriff
(676)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Nature Genetics
(60)
Nature Communications
(29)
Gastroenterology
(22)
Diabetes
(20)
Journal Of Crohn's And Colitis
(20)
Nuclear Fusion
(20)
Diabetologia
(17)
Alimentary Pharmacology & Therapeutics
(16)
Nature
(12)
Zentralblatt Für Chirurgie
(11)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply

Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?

Editorial: delving into the natural history of Crohn’s disease and the impact of medical therapy

Editorial: does anti‐TNF “treatment persistence” always equate to “effective treatment”? Only objective disease assessments can answer the question

Dose intensification strategy influences infliximab pharmacokinetics but not clinical response after the same number of doses

Letter: choosing between ustekinumab and vedolizumab in anti‐TNF refractory Crohn’s disease—the devil is in the detail

Editorial: direct costs are only the tip of the iceberg in inflammatory bowel disease

Dietary sorbitol and mannitol: food content and distinct absorption patterns between healthy individuals and patients with irritable bowel syndrome

Systematic review: fatigue in inflammatory bowel disease

Sleep and physical activity measured by accelerometry in Crohn's disease

Clinical trial: Combination allopurinol‐thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study)

Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease

Editorial: methotrexate vs azathioprine—do differential rates of discontinuation settle the debate? Authors’ reply

Letter: overcoming secondary loss of response to infliximab—it is not the drug, it is how you use it

Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease

Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability

Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy

Predicting response after infliximab salvage in acute severe ulcerative colitis

The Utility of Faecal Calprotectin, Lactoferrin and Other Faecal Biomarkers in Discriminating Endoscopic Activity in Crohn's Disease: A Systematic Review and Meta-Analysis

The synergy of dual faecal immunochemical and faecal calprotectin testing for accurate assessment of endoscopic and histological activity in inflammatory bowel disease

Authors’ Response to Letter to Editor: “Evaluating Serum Free Thiols in Inflammatory Bowel Disease: Contribution of Albumin to Extracellular Free Thiol Status”

Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study

Intestinal Ultrasound in the Assessment of Luminal Crohn’s Disease

New choices, new challenges: Anti-TNF versus anti-integrin molecule therapy in IBD

Challenges and Strategies to Optimising the Quality of Small Bowel Magnetic Resonance Imaging in Crohn’s Disease

Suchergebnisse filtern